Treatment of idiopathic pulmonary fibrosis

Craig E. Daniels, Jay H. Ryu

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive lung disease in most cases, and effective treatment is still lacking. This review examines the current status of treatment options and complexities in the management of patients with IPF. Although optimal therapy for IPF has not been identified, ongoing research efforts warrant reason for optimism. Current management of IPF includes not only judicious use of available pharmacological agents tailored to individual circumstances but also patient education through realistic assessment of prognosis, discussion of pros and cons of pharmacotherapy, early consideration of lung transplantation when applicable, treatment of complications, supportive care, and encouragement to participate in clinical trials.

Original languageEnglish (US)
Pages (from-to)668-676
Number of pages9
JournalSeminars in Respiratory and Critical Care Medicine
Issue number6
StatePublished - Dec 2006


  • Bosentan
  • Idiopathic pulmonary fibrosis
  • N-acetylcysteine
  • Pirfenidone
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Treatment of idiopathic pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this